MedTrace Logo

Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial

NCT03371797 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2018-11-08

No results posted yet for this study

Summary

To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) after 8 weeks of therapy.

Conditions

  • Essential Hypertension

Interventions

DRUG

Valsartan, Amlodipine -

Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent. Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker.

Sponsors & Collaborators

  • PharmEvo Pvt Ltd

    lead INDUSTRY

Principal Investigators

  • Tasneem Ahsan, MBBS · PharmEvo Pvt Ltd

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-20
Primary Completion
2018-10-01
Completion
2018-11-05

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03371797 on ClinicalTrials.gov